Alabama’s biggest insurer will no longer cover OxyContin prescriptions
November 9, 2018Medical Communications Alabama, Blue Cross and Blue Shield, OxyContin, insurance, opioids
The state of Alabama’s biggest insurer Blue Cross and Blue Shield will no long cover opioid painkiller OxyContin. The decision …
Living with fibular hemimelia
November 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cambridge rare disease network, diagnosis, fibular hemimelia, rare disease, therapy
Helena Baker, Vice President of Clinical Strategy at Medical Research Network and a trustee of the newly formed Rare Disease …
Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia
November 8, 2018Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma
Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …
AbbVie sue NHS over hepatitis C drug procurement
November 8, 2018Business Services AbbVie, NHS, britain, court, hep C, hepatitis, ruling
American pharma firm AbbVie are suing Britain’s NHS after claiming that the health service’s procurement of hepatitis C drugs breached …
Investigational antibiotic shows high cure rates in gonorrhoea at Phase 2
November 8, 2018Research and Development National Institute of Allergy and Infectious Diseases, National Institutes of Health, gonorrhoea, pharma, zoliflodacin
A Phase 2 study sponsored by The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National …
Pharma stocks soar after US midterm elections
November 8, 2018Business Services, Manufacturing and Production Shares, Stock, Trump, biotech, pharma, stock market
Despite the threat of a bipartisan pricing plan, pharma stocks have soared after the announcement of the results of the …
AMR superbugs expected to kill 90,000 Britons in the next 30 years
November 8, 2018Research and Development AMR, antimicrobial resistance, infectious diseases, spanish flu
Antibiotic resistant superbugs will kill more than 90,000 British people over the next thirty years if action is not taken …
Bicycle Therapeutics picks up former Pfizer head as new SVP of Pre-Clinical Development
November 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The Cambridge based biotechnology firm Bicycle therapeutics, has announced former Pfizer head Dr Phil Jeffrey as the company’s new Senior …
NICE appoints experienced pharma consultant as Director of NICE Scientific Advice
November 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, government, national institute of health and care excellence, politics, sciences
The National Institute for Health and Care Excellence (NICE) has appointed Jeanette Kusel as Director of NICE Scientific Advice. The …
Prostate cancer researchers win $2m to explore carboplatin therapy
November 7, 2018Research and Development Cancer, carboplatin therapy, prostate cancer
The US Department of Defence has awarded a coalition of researchers – made up of the Prostate Cancer Clinical Research …
Former Celgene CEO Bob Hugin loses in US midterm elections
November 7, 2018Research and Development Bob Hugin, Celgene, Trump, midterms, republican, us politics
Former Celgene CEO Bob Hugin has failed in his bid to win over the people of New Jersey, after voters …
FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival
November 7, 2018Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma
The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …
Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes
November 7, 2018Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes
Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …
Very high concentrations of pharmaceuticals found in animals in Australian streams
November 7, 2018Research and Development Contamination, ecosystems, environment, pharmaceuticals, pollution
More than 60 different pharmaceutical compounds were detected in aquatic invertebrate larvae and riparian predators in six streams near Melbourne, …
UK to push earlier diagnosis and better treatment with 5 AI-driven technology centres
November 6, 2018Manufacturing and Production, Research and Development AI, Leeds, London, Oxford, UK, glasgow, pharma
The UK’s Business Secretary has announced the introduction of five specialist collaborative centres across the UK which with leverage advanced …
Clearside Biomedical shares plummet by 56% after disappointing Phase 3 results
November 6, 2018Manufacturing and Production
Shares in the US-based pharma firm Clearside Biomedical plummeted on Monday after the company announced disappointing phase III trial results …
Health Secretary launches new prevention strategy for NHS
November 6, 2018Manufacturing and Production Matt Hancock, NHS, health, prevention
British Health Secretary Matt Hancock has said that healthcare should focus on prevention, as he launched a long-term strategy intended …
AstraZeneca sells off three drugs in deal worth $350 million
November 6, 2018Manufacturing and Production AstraZeneca, asthma, covis, deal, royalties
Anglo-Swedish multinational AstraZeneca has agreed to sell the rights to three asthma and rhinitis drugs in a deal worth $350 …
J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn
November 6, 2018Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea
Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …
The November 2018 issue of Pharmafocus is available to read online now!
November 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, President trump, Trump, anti vaxxer, brexit, clinical trials, opioid crisis, opioids, pharma, vaccines
As the US continues to battle the demons in its healthcare system, Donald Trump looks like he may finally make …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
